AIMDWHIGH SIGNALFINANCIAL10-K

AIMDW underwent a dramatic strategic pivot from diversified healthcare to AI-based "smelltech" focus while experiencing severe cash depletion that reduced liquidity by nearly 90%.

The company's cash position collapsed from $3.9M to just $417K, creating immediate liquidity concerns despite improved operating cash flow trends. The fundamental business model shift from point-of-care testing and interferon therapeutics to artificial intelligence-based scent digitization represents a complete strategic overhaul that investors must reassess entirely.

Comparing 2026-03-30 vs 2025-03-07View on EDGAR →
FINANCIAL ANALYSIS

AIMDW's balance sheet contracted significantly with current assets declining by nearly three-quarters and stockholders' equity falling by half, primarily driven by the severe cash burn. While operating cash flow improved modestly and current liabilities decreased proportionally, the company's financial runway appears critically constrained. The modest increase in SG&A expenses alongside higher capital expenditures suggests continued investment in the new AI Nose platform despite the cash constraints.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-89.3%
$3.9M→$417K

Cash declined 89.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-73.7%
$4.3M→$1.1M

Current assets declined 73.7% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-72.7%
$4.0M→$1.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+62%
$21K→$35K

Capital expenditure jumped 62% — major investment cycle underway; assess returns on deployment.

Accounts Receivable
Balance Sheet
-60.7%
56→22

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-51.3%
$15.5M→$7.6M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Assets
Balance Sheet
-27.6%
$28.8M→$20.9M

Total assets contracted 27.6% — asset sales, write-downs, or balance sheet optimization underway.

Operating Cash Flow
Cash Flow
+20.5%
-$5.8M→-$4.6M

Operating cash flow grew 20.5% — strong conversion of earnings to cash, healthy business fundamentals.

SG&A Expense
P&L
+17.6%
$5.4M→$6.3M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-07
ADDED
As of March 30, 2026, there were issued and outstanding 7,266,011 shares of the registrant s common stock, par value $ 0.01 , which is the only class of common or voting stock of the registrant.
(the Company ), incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics.
Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA .
Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which we refer to as a smell language model ( SLM ), to digitize scent and volatile organic compound ( VOC ) signals into Smell ID, a machine-readable data format.
AI Nose is initially developed in healthcare-related settings, including point-of-care testing ( POCT ).
+7 more — sign up free →
REMOVED
As of June 30, 2024, the aggregate market value of the shares of common stock outstanding, other than shares held by persons who may be deemed affiliates of the Registrant, computed by reference to the closing price of $ 0.8136 for the Registrant s common stock on June 30, 2024, as reported on Nasdaq Capital Market, was approximately $ 3,350,118 .
(the Company ), incorporated in the State of Texas in 1984, is a diversified healthcare company focused on the development of novel point-of-care testing (the POCT ), therapeutics based on very low-dose interferon alpha (the VELDONA ), and synthetic RNA-driven preventative medicine.
Our product pipeline includes commercial-stage VELDONA Pet supplements, clinical-stage VELDONA human therapeutics and telehealth-friendly POCTs powered by the AI Nose technology platform.
Our vision for AI Nose is to digitize smell, extend application beyond healthcare, and ultimately become AI s nose.
We have historically involved in the research and development of therapeutics based on VELDONA.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →